Oragenics (NYSEAMERICAN:OGEN) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Oragenics (NYSEAMERICAN:OGEN) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Oragenics Stock Up 1.1 %

OGEN stock opened at $3.64 on Tuesday. The business has a 50-day moving average of $3.41 and a 200-day moving average of $3.71. Oragenics has a fifty-two week low of $2.60 and a fifty-two week high of $13.78.

Oragenics (NYSEAMERICAN:OGEN) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($1.51) EPS for the quarter. The company had revenue of $0.01 million during the quarter.

Institutional Investors Weigh In On Oragenics

Several hedge funds have recently modified their holdings of OGEN. State Street Corp lifted its holdings in Oragenics by 8.1% during the 1st quarter. State Street Corp now owns 495,563 shares of the biotechnology company’s stock worth $171,000 after buying an additional 37,338 shares during the period. Renaissance Technologies LLC lifted its holdings in Oragenics by 116.5% during the 2nd quarter. Renaissance Technologies LLC now owns 209,600 shares of the biotechnology company’s stock worth $73,000 after buying an additional 112,800 shares during the period. Finally, Millennium Management LLC lifted its holdings in Oragenics by 591.6% during the 2nd quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company’s stock worth $45,000 after buying an additional 110,119 shares during the period. Institutional investors and hedge funds own 2.07% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.